Limits...
Circulating tumor cells in patients with recurrent or metastatic head and neck carcinoma: prognostic and predictive significance.

Grisanti S, Almici C, Consoli F, Buglione M, Verardi R, Bolzoni-Villaret A, Bianchetti A, Ciccarese C, Mangoni M, Ferrari L, Biti G, Marini M, Ferrari VD, Nicolai P, Magrini SM, Berruti A - PLoS ONE (2014)

Bottom Line: In multivariate analysis, the presence of one CTC or more was associated with a poor prognosis both in terms of progression-free survival (PFS) [Hazard Ratio (HR): 3.068, 95% confidence interval (CI): 1.53-6.13, p 0.002] and overall survival (OS) [HR: 3.0, 95% CI: 1.48-6.0, p 0.002].In conclusion, CTCs are detected in one out of three patients with RM-HNC.The frequency of EGFR expression in CTCs seems to be lower than that expected in the primary tumor.

View Article: PubMed Central - PubMed

Affiliation: Medical Oncology Unit, University of Brescia and Spedali Civili Hospital, Brescia, Italy.

ABSTRACT

Introduction: We investigated the frequency of detection and the prognostic and predictive significance of circulating tumor cells (CTCs) in patients with recurrent/metastatic (R/M) head and neck carcinoma (HNC) before starting systemic therapy.

Patients and methods: Using the CellSearch technology, CTCs were assessed prospectively in peripheral blood of 53 R/M-HNC patients. We performed spiking experiments to test the diagnostic performance of the CellSearch platform in identifying squamous carcinoma cells.

Results: CTCs were identified in 14 (26%) and 22 (41%) patients at baseline and at any time point, respectively. In univariate analysis ≥2 CTCs had a poorer prognostic role than 0-1 CTC. In multivariate analysis, the presence of one CTC or more was associated with a poor prognosis both in terms of progression-free survival (PFS) [Hazard Ratio (HR): 3.068, 95% confidence interval (CI): 1.53-6.13, p 0.002] and overall survival (OS) [HR: 3.0, 95% CI: 1.48-6.0, p 0.002]. A disease control after systemic therapy was obtained in 8% of CTC-positive patients as opposed to 45% in CTC-negative ones (p 0.03). The epidermal growth factor receptor (EGFR) expression was identified in 45% of CTC-positive patients.

Discussion: In conclusion, CTCs are detected in one out of three patients with RM-HNC. CTC detection is a strong prognostic parameter and may be predictive of treatment efficacy. The frequency of EGFR expression in CTCs seems to be lower than that expected in the primary tumor.

Show MeSH

Related in: MedlinePlus

Recovery efficiency of known numbers of spiked A-431 cells from 7.5 mL of blood.The number of spiked cells is plotted against cells recovered by the CellSearch. The Pearson correlation value (R2) indicates strong correlation between spiked and recovered cells.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4126745&req=5

pone-0103918-g001: Recovery efficiency of known numbers of spiked A-431 cells from 7.5 mL of blood.The number of spiked cells is plotted against cells recovered by the CellSearch. The Pearson correlation value (R2) indicates strong correlation between spiked and recovered cells.

Mentions: The approximate number of A-431 cells spiked into the blood of the three healthy donors was plotted against the number of the CellSearch-recovered cells in the samples and regression analysis using the number of observed CTCs versus the number of expected CTCs resulted in a best fit line with a slope of 1.03 (95%CI: 0.77–1.3), an intercept of −1.57 (95%CI:−13.9–10.8), and a correlation coefficient (R2) of 0,9996 (Figure 1). The assay efficiency of recovery was >90%, indicating that the platform was able to detect squamous cells.


Circulating tumor cells in patients with recurrent or metastatic head and neck carcinoma: prognostic and predictive significance.

Grisanti S, Almici C, Consoli F, Buglione M, Verardi R, Bolzoni-Villaret A, Bianchetti A, Ciccarese C, Mangoni M, Ferrari L, Biti G, Marini M, Ferrari VD, Nicolai P, Magrini SM, Berruti A - PLoS ONE (2014)

Recovery efficiency of known numbers of spiked A-431 cells from 7.5 mL of blood.The number of spiked cells is plotted against cells recovered by the CellSearch. The Pearson correlation value (R2) indicates strong correlation between spiked and recovered cells.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4126745&req=5

pone-0103918-g001: Recovery efficiency of known numbers of spiked A-431 cells from 7.5 mL of blood.The number of spiked cells is plotted against cells recovered by the CellSearch. The Pearson correlation value (R2) indicates strong correlation between spiked and recovered cells.
Mentions: The approximate number of A-431 cells spiked into the blood of the three healthy donors was plotted against the number of the CellSearch-recovered cells in the samples and regression analysis using the number of observed CTCs versus the number of expected CTCs resulted in a best fit line with a slope of 1.03 (95%CI: 0.77–1.3), an intercept of −1.57 (95%CI:−13.9–10.8), and a correlation coefficient (R2) of 0,9996 (Figure 1). The assay efficiency of recovery was >90%, indicating that the platform was able to detect squamous cells.

Bottom Line: In multivariate analysis, the presence of one CTC or more was associated with a poor prognosis both in terms of progression-free survival (PFS) [Hazard Ratio (HR): 3.068, 95% confidence interval (CI): 1.53-6.13, p 0.002] and overall survival (OS) [HR: 3.0, 95% CI: 1.48-6.0, p 0.002].In conclusion, CTCs are detected in one out of three patients with RM-HNC.The frequency of EGFR expression in CTCs seems to be lower than that expected in the primary tumor.

View Article: PubMed Central - PubMed

Affiliation: Medical Oncology Unit, University of Brescia and Spedali Civili Hospital, Brescia, Italy.

ABSTRACT

Introduction: We investigated the frequency of detection and the prognostic and predictive significance of circulating tumor cells (CTCs) in patients with recurrent/metastatic (R/M) head and neck carcinoma (HNC) before starting systemic therapy.

Patients and methods: Using the CellSearch technology, CTCs were assessed prospectively in peripheral blood of 53 R/M-HNC patients. We performed spiking experiments to test the diagnostic performance of the CellSearch platform in identifying squamous carcinoma cells.

Results: CTCs were identified in 14 (26%) and 22 (41%) patients at baseline and at any time point, respectively. In univariate analysis ≥2 CTCs had a poorer prognostic role than 0-1 CTC. In multivariate analysis, the presence of one CTC or more was associated with a poor prognosis both in terms of progression-free survival (PFS) [Hazard Ratio (HR): 3.068, 95% confidence interval (CI): 1.53-6.13, p 0.002] and overall survival (OS) [HR: 3.0, 95% CI: 1.48-6.0, p 0.002]. A disease control after systemic therapy was obtained in 8% of CTC-positive patients as opposed to 45% in CTC-negative ones (p 0.03). The epidermal growth factor receptor (EGFR) expression was identified in 45% of CTC-positive patients.

Discussion: In conclusion, CTCs are detected in one out of three patients with RM-HNC. CTC detection is a strong prognostic parameter and may be predictive of treatment efficacy. The frequency of EGFR expression in CTCs seems to be lower than that expected in the primary tumor.

Show MeSH
Related in: MedlinePlus